Search

EP-4736856-A2 - BICYCLIC AMINES AS CDK2 INHIBITORS

EP4736856A2EP 4736856 A2EP4736856 A2EP 4736856A2EP-4736856-A2

Abstract

The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Inventors

  • HUMMEL, Joshua
  • WINTERTON, Sarah
  • XIAO, KAIJIONG
  • WU, LIANGXING
  • YAO, WENQING
  • XU, MEIZHONG
  • YE, MIN
  • CHEN, Yingnan
  • FAVATA, Margaret
  • LO, YVONNE
  • YE, Yingda
  • LI, ZHENWU
  • QIAN, DING-QUAN

Assignees

  • Incyte Corporation

Dates

Publication Date
20260506
Application Date
20201009

Claims (20)

  1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof, for use in a method of treating a disease or disorder associated with CDK2 in a patient, wherein the disease or disorder is cancer, wherein the method comprises administering to the patient a therapeutically effective amount of said compound, or pharmaceutically acceptable salt thereof, in combination with one or more additional pharmaceutical agents, wherein: n is 0, 1, 2, 3, or 4; p is 0, 1, 2, 3, or 4; - - - - is a single or a double bond; X is N, Y is C, and Ring is or X is C, Y is N, and Ring is Z is CR 2 or N; Ring moiety A is 5-10 membered heteroaryl; Ring moiety B is monocyclic 4-7 membered heterocycloalkyl, wherein Ring moiety B is attached to the -NH- group of Formula (I) at a ring member of a saturated or partially saturated ring of said monocyclic 4-7 membered heterocycloalkyl; R 1 is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, 5-10 membered heteroaryl-C 1-4 alkyl, OR a1 , SR a1 , NHOR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)NR c1 (OR a1 ), C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , NR c1 R d1 , NR c1 NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , NR c1 C(O)NR c1 R d1 , C(=NR e1 )R b1 , C(=NR e1 )NR c1 R d1 , NR c1 C(=NR e1 )NR c1 R d1 , NR c1 C(=NR e1 )R b1 , NR c1 S(O)NR c1 R d1 , NR c1 S(O)R b1 , NR c1 S(O) 2 R b1 , NR c1 S(O)(=NR e1 )R b1 , NR c1 S(O) 2 NR c1 R d1 , S(O)R b1 , S(O)NR c1 R d1 , S(O) 2 R b1 , S(O) 2 NR c1 R d1 , OS(O)(=NR e1 )R b1 , OS(O) 2 R b1 , S(O)(=NR e1 )R b1 , SF 5 , P(O)R f1 R g1 , OP(O)(OR h1 )(OR i1 ), P(O)(OR h1 )(OR i1 ), and BR j1 R k1 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents; each R a1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents; or, any R c1 and R d1 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents; each R b1 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents; each R e1 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R f1 and R g1 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R h1 and R i1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R j1 and R k1 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j1 and R k1 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 1A is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a11 , SR a11 , NHOR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)NR c11 (OR a11 ), C(O)OR a11 , OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)OR a11 , NR c11 C(O)NR c11 R d11 , C(=NR e11 )R b11 , C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )NR c11 R d11 , NR c11 C(=NR e11 )R b11 , NR c11 S(O)NR c11 R d11 , NR c11 S(O)R b11 , NR c11 S(O) 2 R b11 , NR c11 S(O)(=NR e11 )R b11 , NR c11 S(O) 2 NR c11 R d11 , S(O)R b11 , S(O)NR c11 R d11 , S(O) 2 R b11 , S(O) 2 NR c11 R d11 , OS(O)(=NR e11 )R b11 , OS(O) 2 R b11 , S(O)(=NR e11 )R b11 , SF 5 , P(O)R f11 R g11 , OP(O)(OR h11 )(OR i11 ), P(O)(OR h11 )(OR i11 ), and BR j11 R k11 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1B substituents; each R a11 , R c11 , and R d11 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1B substituents; or, any R c11 and R d11 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R 1B substituents; each R b11 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 1B substituents; each R e11 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R f11 and R g11 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R h11 and R i11 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R j11 and R k11 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j11 and R k11 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 1B is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a12 , SR a12 , NHOR a12 , C(O)R b12 , C(O)NR c12 R d12 , C(O)NR c12 (OR a12 ), C(O)OR a12 , OC(O)R b12 , OC(O)NR c12 R d12 , NR c12 R d12 , NR c12 NR c12 R d12 , NR c12 C(O)R b12 , NR c12 C(O)OR a12 , NR c12 C(O)NR c12 R d12 , C(=NR e12 )Rb 12 , C(=NR e12 )NR c12 R d12 , NR c12 C(=NR e12 )NR c12 R d12 , NR c12 C(=NR e12 )R b12 , NR c12 S(O)NR c12 R d12 , NR c12 S(O)R b12 , NR c12 S(O) 2 R b12 , NR c12 S(O)(=NR e12 )R b12 , NR c12 S(O) 2 NR c12 R d12 , S(O)R b12 , S(O)NR c12 R d12 , S(O) 2 R b12 , S(O) 2 NR c12 R d12 , OS(O)(=NR e12 )R b12 , OS(O) 2 R b12 , S(O)(=NR e12 )R b12 , SF 5 , P(O)R f12 R g12 , OP(O)(OR h12 )(OR i12 ), P(O)(OR h12 )(OR i12 ), and BR 12 R k12 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R a12 , R c12 , and R d12 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; or, any R c12 and R d12 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R b12 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R e12 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R f12 and R g12 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R h12 and R i12 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R j12 and R k12 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R 12 and R k12 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; R 2 is independently selected from H, D, halo, CN, OH, NO 2 , C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-4 alkoxy, C 1-4 haloalkoxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano-C 1-4 alkyl, HO-C 1-4 alkyl, C 1-4 alkoxy-C 1-4 alkyl, C 3-4 cycloalkyl, thio, C 1-4 alkylthio, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, carbamyl, C 1-4 alkylcarbamyl, di(C 1-4 alkyl)carbamyl, carboxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylcarbonyloxy, C 1-4 alkylcarbonylamino, C 1-4 alkoxycarbonylamino, C 1-4 alkylaminocarbonyloxy, C 1-4 alkylsulfonylamino, aminosulfonyl, C 1-4 alkylaminosulfonyl, di(C 1-4 alkyl)aminosulfonyl, aminosulfonylamino, C 1-4 alkylaminosulfonylamino, di(C 1-4 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-4 alkylaminocarbonylamino, and di(C 1-4 alkyl)aminocarbonylamino; each R 3 is independently selected from H, D, halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, OH, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, cyano-C 1-4 alkyl, HO-C 1-4 alkyl, C 1-3 alkoxy-C 1-4 alkyl, and C 3-4 cycloalkyl; R 4 is selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R 4A substituents; each R 4A is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, 5-10 membered heteroaryl-C 1-4 alkyl, OR a41 , SR a41 , NHOR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)NR c41 (OR a41 ), C(O)OR a41 , OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)OR a41 , NR c41 C(O)NR c41 R d41 , C(=NR e41 )R b41 , C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )NR c41 R d41 , NR c41 C(=NR e41 )R b41 , NR c41 S(O)NR c41 R d41 , NR c41 S(O)R b41 , NR c41 S(O) 2 Rb41 , NR c41 S(O)(=NR e41 )R b41 , NR c41 S(O) 2 NR c41 R d41 , S(O)R b41 , S(O)NR c41 R d41 , S(O) 2 R b41 , S(O) 2 NR c41 R d41 , OS(O) 2 R e41 R b41 , OS(O) 2 R b41 , S(O)(=NR e41 R b41 , SF 5 , P(O)R f41 R g41 , OP(O)(OR h41 )(OR i41 ), P(O)(OR h41 )(OR i41 ), and BR j41 R k41 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 4B substituents; each R a41 , R c41 , and R d41 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 4B substituents; or, any R c41 and R d41 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R 4B substituents; each R b41 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 4B substituents; each R e41 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R f41 and R g41 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R h41 and R i41 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R j41 and R k41 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j41 and R k41 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 10-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 4B is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a42 , SR a42 , NHOR a42 , C(O)R b42 , C(O)NR c42 R d42 , C(O)NR c42 (OR a42 ), C(O)OR a42 , OC(O)R b42 , OC(O)NR c42 R d42 , NR c42 R d42 , NR c42 NR c42 R d42 , NR c42 C(O)R b42 , NR c42 C(O)OR a42 , NR c42 C(O)NR c42 R d42 , C(=NR e42 )R b42 , C(=NR e42 )NR c42 R d42 , NR c42 C(=NR e42 NR c42 R d42 , NR c42 C(=NR e42 )R b42 , NR c42 S(O)NR c42 R d42 , NR c42 S(O)R b42 , NR c42 S(O) 2 R b42 , NR c42 S(O)(=NR e42 )R b42 , NR c42 S(O) 2 NR c42 R d42 , S(O)R b42 , S(O)NR c42 R d42 , S(O) 2 R b42 , S(O) 2 NR c42 R d42 OS(O)(=NR e42 )R b42 , OS(O) 2 R b42 , S(O)(=NR e42 )R b42 , SF 5 , P(O)R f42 R g42 , OP(O)(OR h42 )(OR i42 ), P(O)(OR h42 )(OR i42 ), and BR j42 R k42 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 4C substituents; each R a42 , R c42 , and R d42 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 4C substituents; or, any R c42 and R d42 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R 4C substituents; each R b42 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 4C substituents; each R e42 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R f42 and R g42 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R h42 and R i42 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R j42 and R k42 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R 42 and R k42 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 4c is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a43 , SR a43 , NHOR a43 , C(O)R b43 , C(O)NR c43 R d43 , C(O)NR c43 (OR a43 ), C(O)OR a43 , OC(O)R b43 , OC(O)NR c43 R d43 , NR c43 R d43 , NR c43 NR c43 R d43 , NR c43 C(O)R b43 , NR c43 C(O)OR a43 , NR c43 C(O)NR c43 R d43 , C(=NR e43 )R b43 , C(=NR e43 )NR c43 R d43 , NRc 43 C(=NR e43 )NR c43 R d43 , NR c43 C(=NR e43 )R b43 , NR c43 S(O)NR c43 R d43 , NR c43 S(O)R b43 , NR c43 S(O) 2 R b43 , S(O)(=NR e43 ) R b43 , NR c43 S(O) 2 NR c43 R d43 , S(O)R b43 , S(O)NR c43 R d43 , S(O) 2 R b43 , S(O)NR c43 R d43 , OS(O)=NR e43 )R b43 , OS(O) 2 R b43 , S(O)(=NR e43 )R b43 , SF 5 , P(O)R f43 R g43 , OP(O)(OR h43 )(OR i43 ), P(O)(OR h43 )(OR i43 ), and BR j43 R k43 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R a43 , R c43 , and R d43 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; or, any R c43 and R d43 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R b43 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R e43 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R f43 and R g43 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R h43 and R i43 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R 43 and R k43 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j43 and R k43 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 5 is independently selected from H, D, halo, NO 2 , CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, 5-10 membered heteroaryl-C 1-4 alkyl, OR a5 , SR a5 , NHOR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)NR c5 (OR a5 ), C(O)OR a5 , OC(O)R b5 , OC(O)NR c5 R d5 , NR c5 R d5 , NR c5 NR c5 R d5 , NR c5 C(O)R b5 , NR c5 C(O)OR a5 , NR c5 C(O)NR c5 R d5 , C(=NR e5 )R b5 , C(=NR e5 )NR c5 R d5 , NR c5 C(=NR e5 )NR c5 R d5 , NR c5 C(=NR e5 )R b5 , NR c5 S(O)NR c5 R d5 , NR c5 S(O)R b5 , NR c5 S(O) 2 R b5 , NR c5 S(O)(=NR e5 )R b5 , NR c5 S(O) 2 NR c5 R d5 , S(O)R b5 , S(O)NR c5 R d5 , S(O) 2 R b5 , S(O) 2 NR c5 R d5 , OS(O)(=NR e5 )R b5 , OS(O) 2 R b5 , S(O)(=NR e5 )R b5 , SF 5 , P(O)R f5 R g5 , OP(O)(OR h5 )(OR i5 ), P(O)(OR h5 )(OR i5 ), and BR j5 R k5 ; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R 5A substituents; each R a5 , R c5 , and R d5 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 5A substituents; or, any R c5 and R d5 attached to the same N atom, together with the N atom to which they are attached, form a 4-10 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R 5A substituents; each R b5 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 5A substituents; each R e5 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R f5 and R g5 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R h5 and R i5 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R j5 and R k5 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j5 and R k5 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 5A is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, 5-10 membered heteroaryl-C 1-4 alkyl, OR a51 , SR a51 , NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)NR c51 (OR a51 ), C(O)OR a51 , OC(O)R b51 , OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 NR c51 R d51 , NR c51 C(O)R b51 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , C(=NR e51 )R b51 , C(=NR e51 )NR c51 R d51 , NR c51 C(=NRe 51 )NR c51 R d51 , NR c51 C(=NR e51 )R b51 , NR c51 S(O)NR c51 R d51 , NR c51 S(O)R b51 , NR c51 S(O) 2 R b51 , NR c51 S(O)(=NR e51 )R b51 , NR c51 S(O) 2 NR c51 R d51 , S(O)R b51 , S(O)NR c51 R d51 , S(O) 2 R b51 , S(O) 2 NR c51 R d51 , OS(O)(=NR e51 )R b51 , OS(O) 2 R b51 , S(O)(=NR e51 )R b51 , SF 5 , P(O)R f51 R g51 , OP(O)(OR h51 )(OR i51 ), P(O)(OR h51 )(OR i51 ), and BR j51 R k51 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 5B substituents; each R a51 , R c51 , and R d51 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 5B substituents; or, any R c51 and R d51 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R 5B substituents; each R b51 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 5B substituents; each R e51 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R f51 and R g51 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R h51 and R i51 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C 3-10 cycloalkyl-C 1-4 alkyl, 6-10 membered aryl-C 1-4 alkyl, 4-10 membered heterocycloalkyl-C 1-4 alkyl, and 5-10 membered heteroaryl-C 1-4 alkyl; each R j51 and R k51 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j51 and R k51 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 5B is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a52 , SR a52 , NHOR a52 , C(O)R b52 , C(O)NR c52 R d52 , C(O)NR c52 (OR a52 ), C(O)OR a52 , OC(O)R b52 , OC(O)NR c52 R d52 , NR c52 R d52 , NR c52 NR c52 R d52 , NR c52 C(O)R b52 , NR c52 C(O)OR a52 , NR c52 C(O)NR c52 R d52 , C(=NR e52 )R b52 , C(=NR e52 )NR c52 R d52 , NR c52 C(=NR e52 )NR c52 R d52 , NR c52 C(=NR e52 )R b52 , NR c52 S(O)NR c52 R d52 , NR c52 S(O)R b52 , NR c52 S(O)2R b52 , NR c52 S(O)(=NR e52 )R b52 , NR c52 S(O)2NR c52 R d52 , S(O)R b52 , S(O)NR c52 R d52 , S(O) 2 R b52 , S(O) 2 NR c52 R d52 , OS(O)(=NR e52 )R b52 , OS(O) 2 R b52 , S(O)(=NR e52 )R b52 , SF 5 , P(O)R f52 R g52 , OP(O)(OR h52 )(OR i52 ), P(O)(OR h52 )(OR i52 ), and BR j52 R k52 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 5C substituents; each R a52 , R c52 , and R d52 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 5C substituents; or, any R c52 and R d52 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R 5C substituents; each R b52 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 5C substituents; each R e52 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R f52 and R g52 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R h52 and R i52 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R j52 and R k52 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j52 and R k52 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 5C is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a53 , SR a53 , NHOR a53 , C(O)R b53 , C(O)NR c53 R d53 , C(O)NR c53 (OR a53 ), C(O)OR a53 , OC(O)R b53 , OC(O)NR c53 R d53 , NR c53 R d53 , NR c53 NR c53 R d53 , NR c53 C(O)R b53 , NR c53 C(O)OR a53 , NR c53 C(O)NR c53 R d53 , C(=NR e53 )R b53 , C(=NR e53 )NR c53 R d53 , NR c53 C(=NR e53 )NR c53 R d53 , NR c53 C(=NR e53 )R b53 , NR c53 S(O)NR c53 R d53 , NR c53 S(O)R b53 , NR c53 S(O)2R b53 , NR c53 S(O)(=NR e53 )R b53 , NR c53 S(O)2NR c43 R d53 , S(O)R b53 , S(O)NR c53 R d53 , S(O) 2 R b53 , S(O) 2 NR c53 R c53 , OS(O)(=NR e53 )R b53 , OS(O) 2 R b53 , S(O)(=NR e53 )R b53 , SF 5 , P(O)R f53 R g53 , OP(O)(OR h53 )(OR i53 ), P(O)(OR h53 )(OR í53 ), and BR j53 R k53 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R a53 , R c53 , and R d53 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; or, any R c53 and R d53 attached to the same N atom, together with the N atom to which they are attached, form a 4-7 membered heterocycloalkyl group, which is optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R b53 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents; each R e53 is independently selected from H, OH, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R f53 and R g53 are independently selected from H, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R h53 and R i53 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; each R j53 and R k53 is independently selected from OH, C 1-6 alkoxy, and C 1-6 haloalkoxy; or any R j53 and R k53 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C 1-6 alkyl and C 1-6 haloalkyl; and each R G is independently selected from OH, NO 2 , CN, halo, C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, C 1-3 haloalkyl, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, C 3-7 cycloalkyl, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, thio, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkylsulfonyl, carbamyl, C 1-3 alkylcarbamyl, di(C 1-3 alkyl)carbamyl, carboxy, C 1-3 alkylcarbonyl, C 1-3 alkoxycarbonyl, C 1-3 alkylcarbonyloxy, C 1-3 alkylcarbonylamino, C 1-3 alkoxycarbonylamino, C 1-3 alkylaminocarbonyloxy, C 1-3 alkylsulfonylamino, aminosulfonyl, C 1-3 alkylaminosulfonyl, di(C 1-3 alkyl)aminosulfonyl, aminosulfonylamino, C 1-3 alkylaminosulfonylamino, di(C 1-3 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-3 alkylaminocarbonylamino, and di(C 1-3 alkyl)aminocarbonylamino.
  2. The compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein: (a) R 1 is independently selected from H, halo, CN, NO 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , NR c1 C(O)NR c1 R d1 , NR c1 S(O) 2 R b1 , NR c1 S(O) 2 NR c1 R d1 , S(O) 2 R b1 , and S(O) 2 NR c1 R d1 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents; or (b) R 1 is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-3 alkyl, phenyl-C 1-3 alkyl, 4-7 membered heterocycloalkyl-C 1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, OR a1 , SR a1 , and NR c1 R d1 , wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-3 alkyl, phenyl-C 1-3 alkyl, 4-7 membered heterocycloalkyl-C 1-3 alkyl, and 5-6 membered heteroaryl-C 1-3 alkyl are each optionally substituted with 1 or 2 independently selected R 1A substituents; or (c) R 1 is independently selected from H, C 1-6 alkyl, phenyl, 5-7 membered heterocycloalkyl, OR a1 , SR a1 , and NR c1 R d1 , wherein said C 1-6 alkyl, phenyl, and 5-7 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R 1A substituents; or (d) R 1 is independently selected from H and OR a1 .
  3. The compound or pharmaceutically acceptable salt thereof for use of claim 1 or 2, wherein: (a) each R a1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents; each R b1 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 1A substituents; each R 1A is independently selected from H, D, halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a11 , C(O)R b11 , C(O)NR c11 R d11 , C(O)OR a11 , OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)OR a11 , NR c11 C(O)NR c11 R d11 , NR c11 S(O) 2 R b11 , NR c11 S(O) 2 NR c11 R d11 , S(O) 2 R b11 , and S(O) 2 NR c11 R d11 , wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1B substituents; each R a11 , R c11 , and R d11 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; each R b11 is independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 1B is independently selected from H, D, and OR a12 ; and each R a12 is independently selected from H and C 1-6 alkyl; or (b) each R a1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-3 alkyl, and 4-6 membered heterocycloalkyl-C 1-3 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-3 alkyl, and 4-6 membered heterocycloalkyl-C 1-3 alkyl are each optionally substituted with 1, 2, or 3 independently selected R 1A substituents; each R b1 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-2 alkyl, and 4-6 membered heterocycloalkyl-C 1-2 alkyl, which are each optionally substituted with 1 or 2 independently selected R 1A substituents; and each R 1A is independently selected from H, D, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, OR a11 , and C(O)OR a11 , wherein said C 1-6 alkyl, and C 1-6 haloalkyl, are each optionally substituted with 1, 2, or 3 independently selected R 1B substituents; each R a11 is independently selected from H and C 1-4 alkyl, wherein said C 1-4 alkyl is optionally substituted by 1, 2, or 3 independently selected R 1B substituents; and each R 1B is independently selected from H, D, and O-C 1-4 alkyl.
  4. The compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein R 1 is OR a1 and R a1 is C 1-3 alkyl.
  5. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-4, wherein: (a) R 2 is selected from H, halo, CN, C 1-4 alkyl, C 1-4 haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, OH, C 1-3 alkoxy, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, di(C 1-3 alkyl)amino, cyano-C 1-4 alkyl, HO-C 1-4 alkyl, C 1-3 alkoxy-C 1-4 alkyl, and C 3-4 cycloalkyl; or (b) R 2 is H or halo; or (c) R 2 is H or F.
  6. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-5, wherein Ring moiety B is piperidinyl.
  7. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-6, wherein n is 0 or 1.
  8. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-7, wherein: (a) each R 3 is independently selected from H, F, and methyl; or (b) each R 3 is independently selected from H and methyl.
  9. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-8, wherein: (a) R 4 is selected from C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl; wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R 4A substituents; or (b) R 4 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C 1-4 alkyl; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C 1-4 alkyl are each optionally substituted by 1 or 2 independently selected R 4A substituents; or (c) R 4 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C 1-4 alkyl; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted by 1 or 2 independently selected R 4A substituents; or (d) R 4 is C 1-6 alkyl and C 3-6 cycloalkyl.
  10. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1- 9, wherein: (a) each R 4A is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 , OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)OR a41 , NR c41 C(O)NR c41 R d41 , NR c41 S(O) 2 R b41 , NR c41 S(O) 2 NR c41 R d41 , S(O) 2 R b41 , and S(O) 2 NR c41 R d41 , wherein said C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl are each optionally substituted with 1, 2, or 3 independently selected R 4B substituents; each R a41 , R c41 , and R d41 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl are each optionally substituted with 1 or 2 independently selected R 4B substituents; each R b41 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl, which are each optionally substituted with 1 or 2 independently selected R 4B substituents; each R 4B is independently selected from H, halo, CN, C 1-3 alkyl, C 1-3 haloalkyl, OR a42 , and NR c42 R d42 ; each R a42 , R c42 , and R d42 is independently selected from H, C 1-3 alkyl, and C 1-3 haloalkyl; and each R b42 is independently selected from C 1-3 alkyl and C 1-3 haloalkyl; or (b) each R 4A is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 , OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)OR a41 , NR c41 C(O)NR c41 R d41 , NR c41 S(O) 2 R b41 , NR c41 S(O) 2 NR c41 R d41 , S(O) 2 R b41 , and S(O) 2 NR c41 Rd 41 ; each R a41 , R c41 , and R d41 is independently selected from H, C 1-3 alkyl, and C 1-3 haloalkyl; and each R b41 is independently selected from C 1-3 alkyl and C 1-3 haloalkyl; or (c) each R 4A is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, OR a41 , and NR c41 R d41 ; each R a41 , R c41 , and R d41 is independently selected from H and C 1-3 alkyl, and C 1-3 haloalkyl; and each R b41 is independently C 1-3 alkyl.
  11. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-10, wherein: (a) Ring moiety A is 5-6 membered heteroaryl; or (b) Ring moiety A is 1H-pyrrolo[2,3-b]pyridinyl, pyridinyl, or pyrazolyl; or (c) Ring moiety A is pyrazolyl.
  12. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-11, wherein p is 0 or 1.
  13. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-12, wherein: (a) each R 5 is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a5 , and NR c5 R d5 ; and each R a5 , R c5 , and R d5 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; or (b) each R 5 is independently selected from CH 3 or NH 2 .
  14. The compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein: (a) n is 0, 1, or 2; p is 0, 1, or 2; Ring moiety A is 5-10 membered heteroaryl; Ring moiety B is azetidinyl, pyrrolidinyl or piperidinyl; R 1 is H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-6 cycloalkyl-C 1-3 alkyl, phenyl-C 1-3 alkyl, 4-7 membered heterocycloalkyl-C 1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, OR a1 , SR a1 , and NR c1 R d1 , wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-6 cycloalkyl-C 1-3 alkyl, phenyl-C 1-3 alkyl, 4-7 membered heterocycloalkyl-C 1-3 alkyl, and 5-6 membered heteroaryl-C 1-3 alkyl are each optionally substituted with 1, 2, or 3 independently selected R 1A substituents; each R a1 , R c1 , and R d1 is independently selected from H, D, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, and C 3-7 cycloalkyl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, and C 3-7 cycloalkyl-C 1-4 alkyl are each optionally substituted with 1, 2, or 3 independently selected R 1A substituents; each R 1A is independently selected from H, D, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a11 , C(O)R b11 , C(O)NR c11 R a11 , C(O)OR a11 , OC(O)R b11 , OC(O)NR c11 R d11 , NR c11 R d11 , NR c11 C(O)R b11 , NR c11 C(O)OR a11 , NR c11 C(O)NR c11 R d11 , NR c11 S(O) 2 R b11 , NR c11 S(O) 2 NR c11 R d11 , S(O) 2 R b11 , and S(O) 2 NR c11 R d11 , wherein said C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl are each optionally substituted by 1, 2, or 3 independently selected R 1B substituents; each R a11 , R c11 , and R d11 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; each R b11 is independently selected from C 1-6 alkyl and C 1-6 haloalkyl; each R 1B is independently selected from H, D, and OR a12 ; each R a12 is independently selected from H and C 1-6 alkyl; R 2 is selected from H, halo, CN, C 1-3 alkyl, and C 1-3 haloalkyl; each R 3 is independently selected from H, halo, C 1-3 alkyl, and cyclopropyl; R 4 is selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C 1-4 alkyl; wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C 1-4 alkyl are each optionally substituted by 1 or 2 independently selected R 4A substituents; each R 4A is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a41 , C(O)R b41 , C(O)NR c41 R d41 , C(O)OR a41 , OC(O)R b41 , OC(O)NR c41 R d41 , NR c41 R d41 , NR c41 C(O)R b41 , NR c41 C(O)OR a41 , NR c41 C(O)NR c41 R d41 , NR c41 S(O) 2 R b41 , NR c41 S(O) 2 NR C41 R d41 , S(O) 2 R b41 , and S(O) 2 NR c41 R d41 , wherein said C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl are each optionally substituted with 1, 2, or 3 independently selected R 4B substituents; each R a41 , R c41 , and R d41 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl are each optionally substituted with 1 or 2 independently selected R 4B substituents; each R b41 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, and C 3-4 cycloalkyl, which are each optionally substituted with 1 or 2 independently selected R 4B substituents; each R 4B is independently selected from H, halo, CN, C 1-3 alkyl, C 1-3 haloalkyl, OR a42 , and NR c42 R d42 ; each R a42 , R c42 , and R d42 is independently selected from H, C 1-3 alkyl, and C 1-3 haloalkyl; each R b42 is independently selected from C 1-3 alkyl and C 1-3 haloalkyl. each R 5 is independently selected from H, halo, NO 2 , CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, 5-6 membered heteroaryl-C 1-4 alkyl, OR a5 , SR a5 , NHOR a5 , C(O)R b5 , C(O)NR c5 R d5 , C(O)OR a5 , OC(O)R b5 , OC(O)NR c5 R d5 , NR c5 R d5 , NR c5 C(O)R b5 , NR c5 C(O)OR a5 , NR c5 C(O)NR c5 R d5 , NR c5 S(O) 2 R b5 , NR c5 S(O) 2 NR c5 R d5 , S(O) 2 R b5 , and S(O) 2 NR c5 R d5 ; wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R 5A substituents; each R a5 , R c5 , and R d5 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 5A substituents; and each R b5 is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C 3-7 cycloalkyl-C 1-4 alkyl, phenyl-C 1-4 alkyl, 4-7 membered heterocycloalkyl-C 1-4 alkyl, and 5-6 membered heteroaryl-C 1-4 alkyl, which are each optionally substituted with 1, 2, 3, or 4 independently selected R 5A substituents. each R 5A is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a51 , SR a51 , NHOR a51 , C(O)R b51 , C(O)NR c51 R d51 , C(O)OR a51 , OC(O)R b51 , OC(O)NR c51 R d51 , NR c51 R d51 , NR c51 C(O)R b52 , NR c51 C(O)OR a51 , NR c51 C(O)NR c51 R d51 , NR c51 S(O) 2 R b51 , NR c51 S(O) 2 NR c51 R d51 , S(O) 2 R b51 , and S(O) 2 NR c51 R d51 ; each R a51 , R c51 , and R d51 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; and each R b51 is independently selected from C 1-6 alkyl and C 1-6 haloalkyl; or (b) n is 0 or 1; p is 0 or 1; Ring moiety A is 5-10 membered heteroaryl having 1 or 2 N ring forming atoms; Ring moiety B is piperidinyl; R 1 is independently selected from H, C 1-6 alkyl, phenyl, 5-7 membered heterocycloalkyl, OR a1 , SR a1 , and NR c1 R d1 , wherein said C 1-6 alkyl, phenyl, and 5-7 membered heterocycloalkyl are each optionally substituted with 1 or 2 independently selected R 1A substituents; each R a1 , R c1 , and R d1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-3 alkyl, and 4-6 membered heterocycloalkyl-C 1-3 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-3 alkyl, and 4-6 membered heterocycloalkyl-C 1-3 alkyl are each optionally substituted with 1, 2, or 3 independently selected R 1A substituents; each R 1A is independently selected from D, halo, CN, C 1-3 alkyl, C 1-3 haloalkyl, C 3-4 cycloalkyl, OR a11 , and C(O)OR a11 , wherein said C 1-6 alkyl, and C 1-6 haloalkyl are each optionally substituted with 1, 2, or 3 independently selected R 1B substituents; each R a11 is independently selected from H and C 1-4 alkyl, wherein said C 1-4 alkyl is optionally substituted by 1, 2, or 3 independently selected R 1B substituents; each R 1B is independently selected from H, D, and O-C 1-4 alkyl; R 2 is H or F; each R 3 is independently selected from H or methyl; R 4 is selected from C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C 1-4 alkyl; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl-C 1-4 alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R 4A substituents; each R 4A is independently selected from H, C 1-6 alkyl, OH, and NR c41 R d41 ; each R c41 and R d41 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; each R 5 is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a5 , and NR c5 R d5 ; and each R a5 , R c5 , and R d5 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; or (c) n is 0 or 1; p is 0 or 1; Ring moiety A is 5-10 membered heteroaryl having 1 or 2 N ring forming atoms; Ring moiety B is piperidinyl; R 1 is independently selected from H and OR a1 ; each R a1 is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-3 alkyl, and 4-6 membered heterocycloalkyl-C 1-3 alkyl, wherein said C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-3 alkyl, and 4-6 membered heterocycloalkyl-C 1-3 alkyl are each optionally substituted with 1 or 2 independently selected R 1A substituents; each R 1A is independently selected from C 1-3 alkyl, C 1-3 haloalkyl, C 3-4 cycloalkyl, OH, C 1-3 alkoxy, and C 1-3 haloalkoxy; R 2 is H or F; each R 3 is independently selected from H or methyl; R 4 is selected from C 1-6 alkyl and C 3-6 cycloalkyl; wherein said C 1-6 alkyl and C 3-6 cycloalkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R 4A substituents; each R 4A is independently selected from H and C 1-6 alkyl; each R 5 is independently selected from H, halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-4 cycloalkyl, OR a5 , and NR c5 R d5 ; and each R a5 , R c5 , and R d5 is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl.
  15. The compound or pharmaceutically acceptable salt thereof for use of any one of claims 1-14, wherein: (a) the compound is of Formula (Va), or (Vb), or (Vc), or (Vd): or or or or a pharmaceutically acceptable salt of any of the aforementioned; or (b) the compound is of Formula (VIa), or (VIIa), or (VIIIa), or (IXa): or or or or a pharmaceutically acceptable salt of any of the aforementioned; or (c) the compound is of Formula (VIb), or (VIIIb), or (IXb): or or or a pharmaceutically acceptable salt of any of the aforementioned; or (d) the compound is of Formula (VIc), or (VIIIc), or (IXc): or or or a pharmaceutically acceptable salt of any of the aforementioned.
  16. The compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein: (a) the compound is selected from: N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; 8-ethoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; 8-isobutoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; 8-(cyclopropylmethoxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-((tetrahydro-2 H -pyran-4-yl)oxy)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; 8-(2-methoxyethoxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; 6-fluoro- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; N-(1-(methylsulfonyl)piperidin-4-yl)-6-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyrazin-2-amine; 8-(2,2-difluoroethoxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-(2,2,2-trifluoroethoxy)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-((tetrahydrofuran-3-yl)methoxy)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; 8-ethoxy- N -((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; N -((3 R ,4 S )-1-(cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-8-ethoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; 8-isopropoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine; 8-isobutoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrrolo[2,3-b]pyridin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; and 7-(2-aminopyridin-4-yl)-8-isobutoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine; or a pharmaceutically acceptable salt thereof; or (b) the compound is selected from: 8-ethoxy-7-(3-methyl-1 H -pyrazol-4-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; Methyl 4-((2-((1-(methylsulfonyl)piperidin-4-yl)amino)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-8-yl)oxy)piperidine-1-carboxylate; ( R )-1-(2-(((3 R ,4 S )-4-((8-ethoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5 -a ]pyridin-2-yl)amino)-3-methylpiperidin-1-yl)sulfonyl)ethyl)pyrrolidin-3-ol; 8-ethoxy- N -((3 R ,4 S )-3-methyl-1-((1-methyl-1 H -pyrazol-4-yl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-ethoxy- N -((3 R ,4 S )-3-methyl-1-((2-methyl-2 H -1,2,3-triazol-4-yl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -(1-(methylsulfonyl)piperidin-4-yl)-8-phenyl-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-(4-fluoropiperidin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N 2 -(1-(methylsulfonyl)piperidin-4-yl)- N 8 -phenyl-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridine-2,8-diamine; 8-(4-fluorophenyl)- N- (1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-ethoxy- N -((3 R ,4 S )-3-methyl-1-((3-(piperidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5 -a ]pyridin-2-amine; N -((3 R ,4 S )-1-((3-(dimethylamino)propyl)sulfonyl)-3-methylpiperldin-4-yl)-8-ethoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-ethoxy- N -((3 R ,4 S )-3-methyl-1-((3-(pyrrolidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-(4-(trifluoromethyl)piperidin-1-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-(3-fluoropiperidin-1-yl) -N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-Ethoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-isopropoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-(4-methylpiperidin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-(3-(trifluoromethyl)phenyl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 2-fluoro-4-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-8-yl)benzonitrile; N -(1-(methylsulfonyl)piperidin-4-yl)-8-propyl-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-isopropoxy- N -((3 R ,4 S )-3-methyl-1-((2-(pyrrolidin-1-yl)ethyl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-((4,4-difluorocyclohexyl)oxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-((tetrahydrofuran-3-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-(ethoxy-d 5 )- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-8-((tetrahydro-2 H- pyran-4-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-isopropoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 8-Isobutoxy- N- (1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-(2,2-difluoroethoxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N- (1-(Methylsulfonyl)piperidin-4-yl)-7-(1 H- pyrazol-4-yl)-8-(3,3,3-trifluoropropoxy)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-Butoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-8-propoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-8-(piperidin-1-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -(3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-8-(piperidin-1-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-(4-(2-Methoxyethyl)piperazin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-7-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-8-(pyrrolidin-1-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-((3-(Ethyl(methyl)amino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-((3-(Dimethylamino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-Isopropoxy- N -((3 R ,4 S )-1-((3-(isopropyl(methyl)amino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-Isopropoxy- N -((3 R ,4 S )-3-methyl-1-((3-(piperidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-Isopropoxy-N-((3 R ,4 S )-3-methyl-1-((3-(pyrrolidin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-((3-(Diethylamino)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-Isopropoxy- N -((3 R ,4 S )-3-methyl-1-((3-(4-methylpiperazin-1-yl)propyl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-((3-(4-Ethylpiperazin-1-yl)propyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 8-Isopropoxy- N -((3 R ,4 S )-3-methyl-1-((4-morpholinobutyl)sulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5 -c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-((4-((2,2-Difluoroethyl)amino)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N- ((3 R ,4 S )-1-((4-(Ethyl(methyl)amino)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-((4-(Dimethylamino)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; N -((3 R ,4 S )-1-((4-(( R )-3-(Difluoromethyl)pyrrolidin-1-yl)butyl)sulfonyl)-3-methylpiperidin-4-yl)-8-isopropoxy-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine; 5-Isopropoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-Cyclobutoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-Isobutoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-propoxy-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-(2,2-Difluoroethoxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-(2,2,3,3-tetrafluoropropoxy)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-Cyclopropoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-((3,3-Difluorocyclopentyl)oxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-(Cyclobutylmethoxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-(Cyclopentylmethoxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-5-propoxy-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-Isobutoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-(2,2-Difluoroethoxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-(2,2,3,3-tetrafluoropropoxy)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-(Cyclopropylmethoxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-5-(piperidin-1-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-5-(piperidin-1-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-3-Methyl-1-((1-methyl-1 H -imidazol-4-yl)sulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-Isopropoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-5-isopropoxy-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-5-isopropoxy-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((tetrahydro-2 H pyran-4-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-1-(Ethylsulfonyl)-3-methylpiperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((tetrahydro-2 H -pyran-4-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((tetrahydro-2 H -pyran-4-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Cyclobutoxy- N -((3 R ,4 S )-1-(ethylsulfonyl)-3-methylpiperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Cyclobutoxy- N -((3 R ,4 S )-3-methyl-1-((1-methyl-1 H -pyrazol-4-yl)sulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Cyclobutoxy- N -((3 R ,4 S )-3-methyl-1-((1-methyl-1 H -imidazol-4-yl)sulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R, 4 S )-1 - (Ethylsulfonyl)-3-methylpiperldin-4-yl)-5-isopropoxy-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-1-(Cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-5-isopropoxy-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((tetrahydro-2 H -pyran-4-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; N -((3 R ,4S ) -3-Methyl-1-((1-methyl-1 H -pyrazol-4-yl)sulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-5-((tetrahydro-2 H -pyran-4-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyridin-2-amine; 5-Cyclobutoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Isobutoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-propoxy-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Butoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Isobutoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-5 - propoxy-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Butoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-(3-methylcyclobutoxy)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(3-(Difluoromethyl)cyclobutoxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Cyclopropoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-((4,4-Difluorocyclohexyl)oxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((3-methyltetrahydro-2 H- pyran-4-yl)oxy)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((2-methyltetrahydro-2 H- pyran-4-yl)oxy)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((2-(trifluoromethyl)tetrahydro-2 H -pyran-4-yl)oxy)-[1,2,4]triazolo[1,5 -a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((1-(trifluoromethyl)cyclobutyl)methoxy)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(Cyclopropylmethoxy)- N- ((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(Isopentyloxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Cyclobutoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(3,3-Difluorocyclobutoxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((2-(trifluoromethyl)tetrahydro-2 H -pyran-4-yl)oxy)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-((1-(trifluoromethyl)cyclobutyl)methoxy)-[1,2,4]triazolo[1,5 -a ]pyrazin-2-amine; 5-(Isopentyloxy)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Ethoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(Ethylthio)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(Isopropylthio)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-5-(piperidin-1-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(3,3-Difluoropiperidin-1-yl)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; ( R )-5-(3-Fluoropiperidin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; ( S )-5-(3-Fluoropiperidin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(3,3-Difluoropyrrolidin-1-yl)- N- (1-(methylsulfonyl)piperidin-4-yl)-6-(1 H pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(2-Azabicyclo[2.2.1]heptan-2-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; ( S )-5-(2-Methylpiperidin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; ( S )-5-(2-Methylpyrrolidin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; ( S ) - 5-(3-(Difluoromethyl)pyrrolidin-1-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(7-Azabicyclo[2.2.1]heptan-7-yl)- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -(1-(Methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-5-(3-(trifluoromethyl)piperidin-1-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl-2- d )oxy)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl-1,1,1,3,3,3- d 6 )oxy)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; N -((3 R ,4 S )-3-Methyl-1-(methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl- d 7 )oxy)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-(Cyclopentyloxy)- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; 5-Isopropoxy- N -(1-(methylsulfonyl)piperidin-4-yl)-6-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; and N- (1-(Methylsulfonyl)piperidin-4-yl)-5-((propan-2-yl-2-d)oxy)-6-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- a ]pyrazin-2-amine; or a pharmaceutically acceptable salt thereof.
  17. A compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein the compound is 8-ethoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H -pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine, or a pharmaceutically acceptable salt thereof.
  18. A compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein the compound is N -((3 R ,4 S )-1-(cyclopropylsulfonyl)-3-methylpiperidin-4-yl)-8-ethoxy-7-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine, or a pharmaceutically acceptable salt thereof.
  19. A compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein the compound is 8-isopropoxy- N -((3 R ,4 S )-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1 H- pyrazol-4-yl)-[1,2,4]triazolo[1,5- c ]pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof.
  20. A compound or pharmaceutically acceptable salt thereof for use of claim 1, wherein the compound is 8-(ethoxy-d5)-N-((3R,4S)-3-methyl-1-(methylsulfonyl)piperidin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine, or a pharmaceutically acceptable salt thereof.

Description

This application claims the benefit of priority of U.S. Prov. Appln. No. 62/914,114, filed October 11, 2019, which is incorporated by reference in its entirety. SEQUENCE LISTING The instant application contains a Sequence Listing which has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on October 2, 2020, is named 20443-0634WO1_SL.txt and is 15.3 kilobytes in size. TECHNICAL FIELD This application is directed to bicyclic amines which inhibit cyclin-dependent kinase 2 (CDK2) and are useful for treating cancer. BACKGROUND Cyclin-dependent kinases (CDKs) are a family of serine/threonine kinases. Heterodimerized with regulatory subunits known as cyclins, CDKs become fully activated and regulate key cellular processes including cell cycle progression and cell division (Morgan, D. O., Annu Rev Cell Dev Biol, 1997. 13: 261-91). Uncontrolled proliferation is a hallmark of cancer cells. The deregulation of the CDK activity is associated with abnormal regulation of cell-cycle, and is detected in virtually all forms of human cancers (Sherr, C. J., Science, 1996. 274(5293): 1672-7). CDK2 is of particular interest because deregulation of CDK2 activity occurs frequently in a variety of human cancers. CDK2 plays a crucial role in promoting G1/S transition and S phase progression. In complex with cyclin E (CCNE), CDK2 phosphorylates retinoblastoma pocket protein family members (p107, p130, pRb), leading to de-repression of E2F transcription factors, expression of G1/S transition related genes and transition from G1 to S phase (Henley, S.A. and F.A. Dick, Cell Div, 2012, 7(1): p. 10). This in turn enables activation of CDK2/cyclin A, which phosphorylates endogenous substrates that permit DNA synthesis, replication and centrosome duplication (Ekholm, S.V. and S.I. Reed, Curr Opin Cell Biol, 2000. 12(6): 676-84). It has been reported that the CDK2 pathway influences tumorigenesis mainly through amplification and/or overexpression of CCNE1 and mutations that inactivate CDK2 endogenous inhibitors (e.g., p27), respectively (Xu, X., et al., Biochemistry, 1999. 38(27): 8713-22). CCNE1 copy-number gain and overexpression have been identified in ovarian, gastric, endometrial, breast and other cancers and been associated with poor outcomes in these tumors (Keyomarsi, K., et al., N Engl J Med, 2002. 347(20): 1566-75; Nakayama, N., et al., Cancer, 2010. 116(11): 2621-34; Au-Yeung, G., et al., Clin Cancer Res, 2017. 23(7): 1862-1874; Rosen, D.G., et al., Cancer, 2006. 106(9): 1925-32). Amplification and/or overexpression of CCNE1 also reportedly contribute to trastuzumab resistance in HER2+ breast cancer and resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer (Scaltriti, M., et al., Proc Natl Acad Sci U S A, 2011. 108(9): 3761-6; Herrera-Abreu, M.T., et al., Cancer Res, 2016. 76(8): 2301-13). Various approaches targeting CDK2 have been shown to induce cell cycle arrest and tumor growth inhibition (Chen, YN., et al., Proc Natl Acad Sci U S A, 1999. 96(8): 4325-9; Mendoza, N., et al., Cancer Res, 2003. 63(5): 1020-4). Inhibition of CDK2 also reportedly restores sensitivity to trastuzumab treatment in resistant HER2+ breast tumors in a preclinical model (Scaltriti, supra). These data provide a rationale for considering CDK2 as a potential target for new drug development in cancer associated with deregulated CDK2 activity. In the last decade there has been increasing interest in the development of CDK selective inhibitors. Despite significant efforts, there are no approved agents targeting CDK2 to date (Cicenas, J., et al., Cancers (Basel), 2014. 6(4): p. 2224-42). Therefore it remains a need to discover CDK inhibitors having novel activity profiles, in particular those targeting CDK2. This application is directed to this need and others. SUMMARY The present invention relates to, inter alia, compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein the constituent members are defined herein. The present invention further provides pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention further provides methods of inhibiting CDK2, comprising contacting the CDK2 with a compound described herein, or a pharmaceutically acceptable salt thereof. The present invention further provides methods of inhibiting CDK2 in a patient, comprising administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof. The present invention further provides methods of treating a disease or disorder associated with CDK2 in a patient, comprising administering to the patient a compound described herein, or a pharmaceutically acceptable salt thereof. The present invention further provides compounds described herein, or a pharmaceutically acceptable salt thereof, for use in any of the metho